 | • レポートコード：MRC2-11QY10879 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はアンチセンス・RNAi治療のグローバル市場について調査・分析したレポートです。種類別（RNA干渉、SiRNA、MiRNA、アンチセンスRNA）市場規模、用途別（腫瘍、心血管、腎臓、神経変性、呼吸器、遺伝、感染症）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別アンチセンス・RNAi治療の競争状況、市場シェア ・世界のアンチセンス・RNAi治療市場：種類別市場規模 2015年-2020年（RNA干渉、SiRNA、MiRNA、アンチセンスRNA） ・世界のアンチセンス・RNAi治療市場：種類別市場規模予測 2021年-2026年（RNA干渉、SiRNA、MiRNA、アンチセンスRNA） ・世界のアンチセンス・RNAi治療市場：用途別市場規模 2015年-2020年（腫瘍、心血管、腎臓、神経変性、呼吸器、遺伝、感染症） ・世界のアンチセンス・RNAi治療市場：用途別市場規模予測 2021年-2026年（腫瘍、心血管、腎臓、神経変性、呼吸器、遺伝、感染症） ・北米のアンチセンス・RNAi治療市場分析：米国、カナダ ・ヨーロッパのアンチセンス・RNAi治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのアンチセンス・RNAi治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のアンチセンス・RNAi治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのアンチセンス・RNAi治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Glaxo Smith Kline、Sanofi Aventis / Genzyme、Isis Pharmaceuticals/ Ionis Pharmaceuticals、Arbutus Biopharma Ltd.、Silence Therapeutics、Bio-Path Holdings Inc.、Calando Pharmaceuticals、ICo Therapeutics、Quark Pharmaceuticals、Rexhan Pharmaceuticals、Biomarin/Prosensa、Regulus Therapeutics、Rxi Pharmaceuticals、Silenseed、Dicerna Pharmaceuticals、Sirnaomics Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene “off”.
North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.
Market Analysis and Insights: Global Antisense & RNAi Therapeutics Market
The global Antisense & RNAi Therapeutics market size is projected to reach US$ 1002.6 million by 2026, from US$ 958.5 million in 2020, at a CAGR of 4.3%% during 2021-2026.
Global Antisense & RNAi Therapeutics Scope and Market Size
Antisense & RNAi Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antisense & RNAi Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.
Market segment by Type, the product can be split into
RNA interference
SiRNA
MiRNA
Antisense RNA
Market segment by Application, split into
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Antisense & RNAi Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 RNA interference
1.4.3 SiRNA
1.4.4 MiRNA
1.4.5 Antisense RNA
1.5 Market by Application
1.5.1 Global Antisense & RNAi Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Oncology
1.5.3 Cardiovascular
1.5.4 Renal
1.5.5 Neurodegenerative
1.5.6 Respiratory
1.5.7 Genetic
1.5.8 Infectious Diseases
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Antisense & RNAi Therapeutics Market Perspective (2015-2026)
2.2 Global Antisense & RNAi Therapeutics Growth Trends by Regions
2.2.1 Antisense & RNAi Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Antisense & RNAi Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Antisense & RNAi Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Antisense & RNAi Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Antisense & RNAi Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Antisense & RNAi Therapeutics Players by Market Size
3.1.1 Global Top Antisense & RNAi Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Antisense & RNAi Therapeutics Market Concentration Ratio
3.2.1 Global Antisense & RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Antisense & RNAi Therapeutics Revenue in 2019
3.3 Antisense & RNAi Therapeutics Key Players Head office and Area Served
3.4 Key Players Antisense & RNAi Therapeutics Product Solution and Service
3.5 Date of Enter into Antisense & RNAi Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Antisense & RNAi Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
5.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Antisense & RNAi Therapeutics Market Size (2015-2020)
6.2 Antisense & RNAi Therapeutics Key Players in North America (2019-2020)
6.3 North America Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
6.4 North America Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Antisense & RNAi Therapeutics Market Size (2015-2020)
7.2 Antisense & RNAi Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
7.4 Europe Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Antisense & RNAi Therapeutics Market Size (2015-2020)
8.2 Antisense & RNAi Therapeutics Key Players in China (2019-2020)
8.3 China Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
8.4 China Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Antisense & RNAi Therapeutics Market Size (2015-2020)
9.2 Antisense & RNAi Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
9.4 Japan Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Antisense & RNAi Therapeutics Market Size (2015-2020)
10.2 Antisense & RNAi Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Antisense & RNAi Therapeutics Market Size (2015-2020)
11.2 Antisense & RNAi Therapeutics Key Players in India (2019-2020)
11.3 India Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
11.4 India Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Antisense & RNAi Therapeutics Market Size (2015-2020)
12.2 Antisense & RNAi Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Glaxo Smith Kline
13.1.1 Glaxo Smith Kline Company Details
13.1.2 Glaxo Smith Kline Business Overview
13.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Introduction
13.1.4 Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2015-2020))
13.1.5 Glaxo Smith Kline Recent Development
13.2 Sanofi Aventis / Genzyme
13.2.1 Sanofi Aventis / Genzyme Company Details
13.2.2 Sanofi Aventis / Genzyme Business Overview
13.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Introduction
13.2.4 Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
13.2.5 Sanofi Aventis / Genzyme Recent Development
13.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
13.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details
13.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
13.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Introduction
13.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
13.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
13.4 Arbutus Biopharma Ltd.
13.4.1 Arbutus Biopharma Ltd. Company Details
13.4.2 Arbutus Biopharma Ltd. Business Overview
13.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Introduction
13.4.4 Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
13.4.5 Arbutus Biopharma Ltd. Recent Development
13.5 Silence Therapeutics
13.5.1 Silence Therapeutics Company Details
13.5.2 Silence Therapeutics Business Overview
13.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Introduction
13.5.4 Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
13.5.5 Silence Therapeutics Recent Development
13.6 Bio-Path Holdings Inc.
13.6.1 Bio-Path Holdings Inc. Company Details
13.6.2 Bio-Path Holdings Inc. Business Overview
13.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Introduction
13.6.4 Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
13.6.5 Bio-Path Holdings Inc. Recent Development
13.7 Calando Pharmaceuticals
13.7.1 Calando Pharmaceuticals Company Details
13.7.2 Calando Pharmaceuticals Business Overview
13.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Introduction
13.7.4 Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
13.7.5 Calando Pharmaceuticals Recent Development
13.8 ICo Therapeutics
13.8.1 ICo Therapeutics Company Details
13.8.2 ICo Therapeutics Business Overview
13.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Introduction
13.8.4 ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
13.8.5 ICo Therapeutics Recent Development
13.9 Quark Pharmaceuticals
13.9.1 Quark Pharmaceuticals Company Details
13.9.2 Quark Pharmaceuticals Business Overview
13.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Introduction
13.9.4 Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
13.9.5 Quark Pharmaceuticals Recent Development
13.10 Rexhan Pharmaceuticals
13.10.1 Rexhan Pharmaceuticals Company Details
13.10.2 Rexhan Pharmaceuticals Business Overview
13.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Introduction
13.10.4 Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
13.10.5 Rexhan Pharmaceuticals Recent Development
13.11 Biomarin/Prosensa
10.11.1 Biomarin/Prosensa Company Details
10.11.2 Biomarin/Prosensa Business Overview
10.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Introduction
10.11.4 Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
10.11.5 Biomarin/Prosensa Recent Development
13.12 Regulus Therapeutics
10.12.1 Regulus Therapeutics Company Details
10.12.2 Regulus Therapeutics Business Overview
10.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Introduction
10.12.4 Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
10.12.5 Regulus Therapeutics Recent Development
13.13 Rxi Pharmaceuticals
10.13.1 Rxi Pharmaceuticals Company Details
10.13.2 Rxi Pharmaceuticals Business Overview
10.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Introduction
10.13.4 Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
10.13.5 Rxi Pharmaceuticals Recent Development
13.14 Silenseed
10.14.1 Silenseed Company Details
10.14.2 Silenseed Business Overview
10.14.3 Silenseed Antisense & RNAi Therapeutics Introduction
10.14.4 Silenseed Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
10.14.5 Silenseed Recent Development
13.15 Dicerna Pharmaceuticals
10.15.1 Dicerna Pharmaceuticals Company Details
10.15.2 Dicerna Pharmaceuticals Business Overview
10.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Introduction
10.15.4 Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
10.15.5 Dicerna Pharmaceuticals Recent Development
13.16 Sirnaomics Inc.
10.16.1 Sirnaomics Inc. Company Details
10.16.2 Sirnaomics Inc. Business Overview
10.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Introduction
10.16.4 Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
10.16.5 Sirnaomics Inc. Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Antisense & RNAi Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Antisense & RNAi Therapeutics Revenue
Table 3. Ranking of Global Top Antisense & RNAi Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of RNA interference
Table 6. Key Players of SiRNA
Table 7. Key Players of MiRNA
Table 8. Key Players of Antisense RNA
Table 9. Global Antisense & RNAi Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Antisense & RNAi Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Antisense & RNAi Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Antisense & RNAi Therapeutics Market Share by Regions (2015-2020)
Table 13. Global Antisense & RNAi Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Antisense & RNAi Therapeutics Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Antisense & RNAi Therapeutics Market Growth Strategy
Table 19. Main Points Interviewed from Key Antisense & RNAi Therapeutics Players
Table 20. Global Antisense & RNAi Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 21. Global Antisense & RNAi Therapeutics Market Share by Players (2015-2020)
Table 22. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense & RNAi Therapeutics as of 2019)
Table 23. Global Antisense & RNAi Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Antisense & RNAi Therapeutics Product Solution and Service
Table 26. Date of Enter into Antisense & RNAi Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Antisense & RNAi Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 29. Global Antisense & RNAi Therapeutics Market Size Share by Type (2015-2020)
Table 30. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2021-2026)
Table 31. Global Antisense & RNAi Therapeutics Market Size Share by Application (2015-2020)
Table 32. Global Antisense & RNAi Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 33. Global Antisense & RNAi Therapeutics Market Size Share by Application (2021-2026)
Table 34. North America Key Players Antisense & RNAi Therapeutics Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Antisense & RNAi Therapeutics Market Share (2019-2020)
Table 36. North America Antisense & RNAi Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. North America Antisense & RNAi Therapeutics Market Share by Type (2015-2020)
Table 38. North America Antisense & RNAi Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 39. North America Antisense & RNAi Therapeutics Market Share by Application (2015-2020)
Table 40. Europe Key Players Antisense & RNAi Therapeutics Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Antisense & RNAi Therapeutics Market Share (2019-2020)
Table 42. Europe Antisense & RNAi Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Antisense & RNAi Therapeutics Market Share by Type (2015-2020)
Table 44. Europe Antisense & RNAi Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Antisense & RNAi Therapeutics Market Share by Application (2015-2020)
Table 46. China Key Players Antisense & RNAi Therapeutics Revenue (2019-2020) (Million US$)
Table 47. China Key Players Antisense & RNAi Therapeutics Market Share (2019-2020)
Table 48. China Antisense & RNAi Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 49. China Antisense & RNAi Therapeutics Market Share by Type (2015-2020)
Table 50. China Antisense & RNAi Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 51. China Antisense & RNAi Therapeutics Market Share by Application (2015-2020)
Table 52. Japan Key Players Antisense & RNAi Therapeutics Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Antisense & RNAi Therapeutics Market Share (2019-2020)
Table 54. Japan Antisense & RNAi Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Antisense & RNAi Therapeutics Market Share by Type (2015-2020)
Table 56. Japan Antisense & RNAi Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Antisense & RNAi Therapeutics Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Antisense & RNAi Therapeutics Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Antisense & RNAi Therapeutics Market Share (2019-2020)
Table 60. Southeast Asia Antisense & RNAi Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Antisense & RNAi Therapeutics Market Share by Type (2015-2020)
Table 62. Southeast Asia Antisense & RNAi Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Antisense & RNAi Therapeutics Market Share by Application (2015-2020)
Table 64. India Key Players Antisense & RNAi Therapeutics Revenue (2019-2020) (Million US$)
Table 65. India Key Players Antisense & RNAi Therapeutics Market Share (2019-2020)
Table 66. India Antisense & RNAi Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 67. India Antisense & RNAi Therapeutics Market Share by Type (2015-2020)
Table 68. India Antisense & RNAi Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 69. India Antisense & RNAi Therapeutics Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Antisense & RNAi Therapeutics Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Antisense & RNAi Therapeutics Market Share (2019-2020)
Table 72. Central & South America Antisense & RNAi Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Antisense & RNAi Therapeutics Market Share by Type (2015-2020)
Table 74. Central & South America Antisense & RNAi Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Antisense & RNAi Therapeutics Market Share by Application (2015-2020)
Table 76. Glaxo Smith Kline Company Details
Table 77. Glaxo Smith Kline Business Overview
Table 78. Glaxo Smith Kline Product
Table 79. Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 80. Glaxo Smith Kline Recent Development
Table 81. Sanofi Aventis / Genzyme Company Details
Table 82. Sanofi Aventis / Genzyme Business Overview
Table 83. Sanofi Aventis / Genzyme Product
Table 84. Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 85. Sanofi Aventis / Genzyme Recent Development
Table 86. Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details
Table 87. Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
Table 88. Isis Pharmaceuticals/ Ionis Pharmaceuticals Product
Table 89. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 90. Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
Table 91. Arbutus Biopharma Ltd. Company Details
Table 92. Arbutus Biopharma Ltd. Business Overview
Table 93. Arbutus Biopharma Ltd. Product
Table 94. Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 95. Arbutus Biopharma Ltd. Recent Development
Table 96. Silence Therapeutics Company Details
Table 97. Silence Therapeutics Business Overview
Table 98. Silence Therapeutics Product
Table 99. Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 100. Silence Therapeutics Recent Development
Table 101. Bio-Path Holdings Inc. Company Details
Table 102. Bio-Path Holdings Inc. Business Overview
Table 103. Bio-Path Holdings Inc. Product
Table 104. Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 105. Bio-Path Holdings Inc. Recent Development
Table 106. Calando Pharmaceuticals Company Details
Table 107. Calando Pharmaceuticals Business Overview
Table 108. Calando Pharmaceuticals Product
Table 109. Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 110. Calando Pharmaceuticals Recent Development
Table 111. ICo Therapeutics Business Overview
Table 112. ICo Therapeutics Product
Table 113. ICo Therapeutics Company Details
Table 114. ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 115. ICo Therapeutics Recent Development
Table 116. Quark Pharmaceuticals Company Details
Table 117. Quark Pharmaceuticals Business Overview
Table 118. Quark Pharmaceuticals Product
Table 119. Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 120. Quark Pharmaceuticals Recent Development
Table 121. Rexhan Pharmaceuticals Company Details
Table 122. Rexhan Pharmaceuticals Business Overview
Table 123. Rexhan Pharmaceuticals Product
Table 124. Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 125. Rexhan Pharmaceuticals Recent Development
Table 126. Biomarin/Prosensa Company Details
Table 127. Biomarin/Prosensa Business Overview
Table 128. Biomarin/Prosensa Product
Table 129. Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 130. Biomarin/Prosensa Recent Development
Table 131. Regulus Therapeutics Company Details
Table 132. Regulus Therapeutics Business Overview
Table 133. Regulus Therapeutics Product
Table 134. Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 135. Regulus Therapeutics Recent Development
Table 136. Rxi Pharmaceuticals Company Details
Table 137. Rxi Pharmaceuticals Business Overview
Table 138. Rxi Pharmaceuticals Product
Table 139. Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 140. Rxi Pharmaceuticals Recent Development
Table 141. Silenseed Company Details
Table 142. Silenseed Business Overview
Table 143. Silenseed Product
Table 144. Silenseed Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 145. Silenseed Recent Development
Table 146. Dicerna Pharmaceuticals Company Details
Table 147. Dicerna Pharmaceuticals Business Overview
Table 148. Dicerna Pharmaceuticals Product
Table 149. Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 150. Dicerna Pharmaceuticals Recent Development
Table 151. Sirnaomics Inc. Company Details
Table 152. Sirnaomics Inc. Business Overview
Table 153. Sirnaomics Inc. Product
Table 154. Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2015-2020) (Million US$)
Table 155. Sirnaomics Inc. Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antisense & RNAi Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. RNA interference Features
Figure 3. SiRNA Features
Figure 4. MiRNA Features
Figure 5. Antisense RNA Features
Figure 6. Global Antisense & RNAi Therapeutics Market Share by Application: 2020 VS 2026
Figure 7. Oncology Case Studies
Figure 8. Cardiovascular Case Studies
Figure 9. Renal Case Studies
Figure 10. Neurodegenerative Case Studies
Figure 11. Respiratory Case Studies
Figure 12. Genetic Case Studies
Figure 13. Infectious Diseases Case Studies
Figure 14. Antisense & RNAi Therapeutics Report Years Considered
Figure 15. Global Antisense & RNAi Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global Antisense & RNAi Therapeutics Market Share by Regions: 2020 VS 2026
Figure 17. Global Antisense & RNAi Therapeutics Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global Antisense & RNAi Therapeutics Market Share by Players in 2019
Figure 20. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense & RNAi Therapeutics as of 2019
Figure 21. The Top 10 and 5 Players Market Share by Antisense & RNAi Therapeutics Revenue in 2019
Figure 22. North America Antisense & RNAi Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe Antisense & RNAi Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China Antisense & RNAi Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan Antisense & RNAi Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia Antisense & RNAi Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India Antisense & RNAi Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America Antisense & RNAi Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Bottom-up and Top-down Approaches for This Report
Figure 30. Data Triangulation
Figure 31. Key Executives Interviewed
増殖性糖尿病性網膜症治療治療薬の世界市場（～2026年） Market Analysis and Insights: Global Proliferative Diabetic Retinopathy Therapeutics Market The global Proliferative Diabetic Retinopathy Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Proliferative Diabe…- 糖尿病網膜症（DR）の世界市場（～2026年） Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabe…
- デュシェンヌ型筋ジストロフィー薬の世界市場（～2026年） Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essenti…
- 急性腎不全治療薬の世界市場（～2026年） Acute renal failure is a sudden loss of kidney’s ability to eliminate excess fluids, salts and metabolic waste from the body. It leads to accumulation of metabolic waste and electrolytes in the body which can be life-threatening. Kidney eliminates creatinine (Metabolic waste) from the body. Acute re…
- 高度腎細胞癌治療薬の世界市場（～2026年） Advanced renal cell carcinoma is associated with a type of kidney cancer that appears in the covering of the proximal complex tubule. The convoluted tubule is a very small part of tubes in the kidney that helps in transportation of unwanted particles from the blood to the urine. Advanced renal cell …